• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

使用TOOKAD®可溶性制剂进行的血管靶向光动力疗法治疗局限性前列腺癌：治疗程序的标准化

Vascular-targeted photodynamic therapy with TOOKAD® Soluble in localized prostate cancer: standardization of the procedure.

作者信息

Azzouzi Abdel-Rahmene, Lebdai Souhil, Benzaghou Fawzi, Stief Christian

机构信息

Urology Department, CHU Angers, 4 rue Larrey, 49933, Angers Cedex 9, France,

出版信息

World J Urol. 2015 Jul;33(7):937-44. doi: 10.1007/s00345-015-1535-2. Epub 2015 Mar 19.

DOI:10.1007/s00345-015-1535-2
PMID:25786708
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4480332/
Abstract

INTRODUCTION

Vascular-targeted photodynamic therapy with TOOKAD(®) Soluble is an innovative focal therapy procedure assessed in localized prostate cancer treatment.

MATERIALS AND METHODS

This mini-invasive technique destroys targeted tissues using a photosensitizer [TOOKAD(®) Soluble (WST11), STEBA Biotech] activated by laser light in the presence of oxygen. Its application for prostate cancer requires intravenous infusion of TOOKAD(®) Soluble and the illumination of the targeted area by transperineal optical fibers inserted under trans-rectal ultrasound guidance under general anesthesia.

CONCLUSION

Based on the experience gained through hundreds of procedures, we describe here the standardized technique of vascular-targeted photodynamic therapy with TOOKAD(®) Soluble defined during the phase II and III trials.

摘要

引言

使用TOOKAD(®) Soluble进行的血管靶向光动力疗法是一种用于局部前列腺癌治疗的创新性局部治疗方法。

材料与方法

这种微创技术利用在氧气存在下由激光激活的光敏剂[TOOKAD(®) Soluble（WST11），STEBA生物技术公司]破坏靶向组织。其在前列腺癌中的应用需要静脉输注TOOKAD(®) Soluble，并在全身麻醉下经直肠超声引导下经会阴插入光纤对靶向区域进行照射。

结论

基于数百例手术所积累的经验，我们在此描述在II期和III期试验中确定的使用TOOKAD(®) Soluble进行血管靶向光动力疗法的标准化技术。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ada/4480332/f074b2bcdb7a/345_2015_1535_Fig10_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ada/4480332/2eae1a6292ce/345_2015_1535_Fig1a_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ada/4480332/ed68f447e871/345_2015_1535_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ada/4480332/5ba02bb16ff4/345_2015_1535_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ada/4480332/e0c7175f75b6/345_2015_1535_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ada/4480332/065ce03e5376/345_2015_1535_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ada/4480332/7664c69049eb/345_2015_1535_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ada/4480332/1499434d697a/345_2015_1535_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ada/4480332/45cf12df43ba/345_2015_1535_Fig8_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ada/4480332/8c3341145399/345_2015_1535_Fig9_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ada/4480332/f074b2bcdb7a/345_2015_1535_Fig10_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ada/4480332/2eae1a6292ce/345_2015_1535_Fig1a_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ada/4480332/ed68f447e871/345_2015_1535_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ada/4480332/5ba02bb16ff4/345_2015_1535_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ada/4480332/e0c7175f75b6/345_2015_1535_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ada/4480332/065ce03e5376/345_2015_1535_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ada/4480332/7664c69049eb/345_2015_1535_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ada/4480332/1499434d697a/345_2015_1535_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ada/4480332/45cf12df43ba/345_2015_1535_Fig8_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ada/4480332/8c3341145399/345_2015_1535_Fig9_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ada/4480332/f074b2bcdb7a/345_2015_1535_Fig10_HTML.jpg

相似文献

1
Vascular-targeted photodynamic therapy with TOOKAD® Soluble in localized prostate cancer: standardization of the procedure.使用TOOKAD®可溶性制剂进行的血管靶向光动力疗法治疗局限性前列腺癌：治疗程序的标准化
World J Urol. 2015 Jul;33(7):937-44. doi: 10.1007/s00345-015-1535-2. Epub 2015 Mar 19.
2
TOOKAD® Soluble focal therapy: pooled analysis of three phase II studies assessing the minimally invasive ablation of localized prostate cancer.TOOKAD® 可溶性聚焦疗法：三项评估局限性前列腺癌微创消融的II期研究的汇总分析。
World J Urol. 2015 Jul;33(7):945-53. doi: 10.1007/s00345-015-1505-8. Epub 2015 Feb 25.
3
Endoscopic vascular targeted photodynamic therapy with the photosensitizer WST11 for benign prostatic hyperplasia in the preclinical dog model.经内镜血管靶向光动力疗法联合光敏剂 WST11 治疗犬良性前列腺增生的临床前研究。
J Urol. 2013 Nov;190(5):1946-53. doi: 10.1016/j.juro.2013.05.014. Epub 2013 May 13.
4
TOOKAD(®) Soluble vascular-targeted photodynamic (VTP) therapy: determination of optimal treatment conditions and assessment of effects in patients with localised prostate cancer.TOOKAD(®) 可溶性血管靶向光动力（VTP）疗法：确定局部前列腺癌的最佳治疗条件和评估疗效。
BJU Int. 2013 Oct;112(6):766-74. doi: 10.1111/bju.12265.
5
Vascular targeted photodynamic therapy with TOOKAD® Soluble (WST11) in localized prostate cancer: efficiency of automatic pre-treatment planning.使用TOOKAD® Soluble（WST11）进行血管靶向光动力疗法治疗局限性前列腺癌：自动预处理计划的效率
Lasers Med Sci. 2017 Aug;32(6):1301-1307. doi: 10.1007/s10103-017-2241-7. Epub 2017 Jun 1.
6
Determination of optimal drug dose and light dose index to achieve minimally invasive focal ablation of localised prostate cancer using WST11-vascular-targeted photodynamic (VTP) therapy.使用WST11-血管靶向光动力（VTP）疗法确定实现局限性前列腺癌微创聚焦消融的最佳药物剂量和光剂量指数。
BJU Int. 2015 Dec;116(6):888-96. doi: 10.1111/bju.12816. Epub 2015 Apr 21.
7
[Treatment of localized prostate cancer by vascular-targeted photodynamic therapy with WST11].[采用WST11进行血管靶向光动力疗法治疗局限性前列腺癌]
Prog Urol. 2014 Nov;24(14):911-4. doi: 10.1016/j.purol.2014.08.002. Epub 2014 Sep 5.
8
A model to estimate the outcome of prostate cancer photodynamic therapy with TOOKAD Soluble WST11.采用 TOOKAD Soluble WST11 预测前列腺癌光动力疗法效果的模型。
Phys Med Biol. 2011 Aug 7;56(15):4771-83. doi: 10.1088/0031-9155/56/15/009. Epub 2011 Jul 13.
9
Photodynamic therapy with Pd-Bacteriopheophorbide (TOOKAD): successful in vivo treatment of human prostatic small cell carcinoma xenografts.钯-细菌脱镁叶绿酸光动力疗法（TOOKAD）：成功对人前列腺小细胞癌异种移植瘤进行体内治疗
Int J Cancer. 2003 May 10;104(6):782-9. doi: 10.1002/ijc.11002.
10
Vascular targeted photodynamic therapy with palladium-bacteriopheophorbide photosensitizer for recurrent prostate cancer following definitive radiation therapy: assessment of safety and treatment response.采用钯-细菌脱镁叶绿酸光敏剂的血管靶向光动力疗法治疗根治性放疗后复发性前列腺癌：安全性及治疗反应评估
J Urol. 2007 Nov;178(5):1974-9; discussion 1979. doi: 10.1016/j.juro.2007.07.036. Epub 2007 Sep 17.

引用本文的文献

1
The Safety and Efficacy of Vascular-Targeted Photodynamic Therapy in Low-Risk Prostate Cancer.血管靶向光动力疗法在低危前列腺癌中的安全性和有效性
Cancers (Basel). 2025 Feb 16;17(4):661. doi: 10.3390/cancers17040661.
2
The use of focal therapy for the treatment of prostate cancer in Canada Where are we, how did we get here, and where are we going?聚焦疗法在加拿大用于治疗前列腺癌的情况：我们现在处于什么位置，我们是如何走到这一步的，以及我们将走向何方？
Can Urol Assoc J. 2025 Feb;19(2):63-72. doi: 10.5489/cuaj.8888.
3
Refining antimicrobial photodynamic therapy: effect of charge distribution and central metal ion in fluorinated porphyrins on effective control of planktonic and biofilm bacterial forms.

本文引用的文献

1
Determination of optimal drug dose and light dose index to achieve minimally invasive focal ablation of localised prostate cancer using WST11-vascular-targeted photodynamic (VTP) therapy.使用WST11-血管靶向光动力（VTP）疗法确定实现局限性前列腺癌微创聚焦消融的最佳药物剂量和光剂量指数。
BJU Int. 2015 Dec;116(6):888-96. doi: 10.1111/bju.12816. Epub 2015 Apr 21.
2
TOOKAD(®) Soluble vascular-targeted photodynamic (VTP) therapy: determination of optimal treatment conditions and assessment of effects in patients with localised prostate cancer.TOOKAD(®) 可溶性血管靶向光动力（VTP）疗法：确定局部前列腺癌的最佳治疗条件和评估疗效。
BJU Int. 2013 Oct;112(6):766-74. doi: 10.1111/bju.12265.
3
优化抗菌光动力疗法：氟化卟啉中电荷分布和中心金属离子对浮游和生物膜细菌形态有效控制的影响
Photochem Photobiol Sci. 2024 Mar;23(3):539-560. doi: 10.1007/s43630-024-00538-1. Epub 2024 Mar 8.
4
Versatile Design of Organic Polymeric Nanoparticles for Photodynamic Therapy of Prostate Cancer.用于前列腺癌光动力治疗的有机聚合物纳米颗粒的多功能设计
ACS Mater Au. 2023 Nov 6;4(1):14-29. doi: 10.1021/acsmaterialsau.3c00060. eCollection 2024 Jan 10.
5
The use of nanomaterials in advancing photodynamic therapy (PDT) for deep-seated tumors and synergy with radiotherapy.纳米材料在推进深部肿瘤光动力疗法（PDT）及与放射疗法协同作用中的应用。
Front Bioeng Biotechnol. 2023 Oct 2;11:1250804. doi: 10.3389/fbioe.2023.1250804. eCollection 2023.
6
Photodynamic therapy, priming and optical imaging: Potential co-conspirators in treatment design and optimization - a Thomas Dougherty Award for Excellence in PDT paper.光动力疗法、预处理与光学成像：治疗设计与优化中的潜在协同因素——一篇荣获托马斯·多尔蒂光动力疗法卓越奖的论文
J Porphyr Phthalocyanines. 2020 Nov-Dec;24(11n12):1320-1360. doi: 10.1142/s1088424620300098.
7
Shining a Light on Prostate Cancer: Photodynamic Therapy and Combination Approaches.聚焦前列腺癌：光动力疗法及联合治疗方法
Pharmaceutics. 2023 Jun 19;15(6):1767. doi: 10.3390/pharmaceutics15061767.
8
Trial watch: an update of clinical advances in photodynamic therapy and its immunoadjuvant properties for cancer treatment.试验观察：光动力疗法及其免疫佐剂特性在癌症治疗中的临床进展更新。
Oncoimmunology. 2023 Jun 18;12(1):2226535. doi: 10.1080/2162402X.2023.2226535. eCollection 2023.
9
Interrogating biological systems using visible-light-powered catalysis.利用可见光催化对生物系统进行探究。
Nat Rev Chem. 2021 May;5(5):322-337. doi: 10.1038/s41570-021-00265-6. Epub 2021 Mar 29.
10
Cytotoxic Effects of New Palladium(II) Complexes with Thiazine or Thiazoline Derivative Ligands in Tumor Cell Lines.新型含噻嗪或噻唑啉衍生物配体的钯（II）配合物对肿瘤细胞系的细胞毒性作用
Pharmaceutics. 2023 Feb 18;15(2):696. doi: 10.3390/pharmaceutics15020696.
Histopathology of prostate tissue after vascular-targeted photodynamic therapy for localized prostate cancer.
前列腺癌局限性经血管靶向光动力治疗后的前列腺组织病理学。
Virchows Arch. 2013 Oct;463(4):547-52. doi: 10.1007/s00428-013-1454-9. Epub 2013 Aug 16.
4
A model to estimate the outcome of prostate cancer photodynamic therapy with TOOKAD Soluble WST11.采用 TOOKAD Soluble WST11 预测前列腺癌光动力疗法效果的模型。
Phys Med Biol. 2011 Aug 7;56(15):4771-83. doi: 10.1088/0031-9155/56/15/009. Epub 2011 Jul 13.
5
Photodynamic therapy for prostate cancer--a review of current status and future promise.前列腺癌的光动力疗法——现状与未来展望综述
Nat Clin Pract Urol. 2009 Jan;6(1):18-30. doi: 10.1038/ncpuro1274.
6
The microenvironment effect on the generation of reactive oxygen species by Pd-bacteriopheophorbide.微环境对钯-细菌脱镁叶绿素产生活性氧的影响。
J Am Chem Soc. 2005 May 4;127(17):6487-97. doi: 10.1021/ja046210j.
7
Novel water-soluble bacteriochlorophyll derivatives for vascular-targeted photodynamic therapy: synthesis, solubility, phototoxicity and the effect of serum proteins.用于血管靶向光动力疗法的新型水溶性细菌叶绿素衍生物：合成、溶解性、光毒性及血清蛋白的影响
Photochem Photobiol. 2005 Jul-Aug;81(4):983-93. doi: 10.1562/2004-12-01-RA-389.
8
The present and future role of photodynamic therapy in cancer treatment.光动力疗法在癌症治疗中的当前及未来作用。
Lancet Oncol. 2004 Aug;5(8):497-508. doi: 10.1016/S1470-2045(04)01529-3.
9
Perfusion, oxygenation status and growth of experimental tumors upon photodynamic therapy with Pd-bacteriopheophorbide.钯-细菌脱镁叶绿酸光动力治疗后实验性肿瘤的灌注、氧合状态及生长情况
Int J Oncol. 2004 Jun;24(6):1505-11.
10
Selectivity of the photosensitiser Tookad for photodynamic therapy evaluated in the Syrian golden hamster cheek pouch tumour model.在叙利亚金黄地鼠颊囊肿瘤模型中评估光动力疗法光敏剂Tookad的选择性。
Br J Cancer. 2003 Dec 15;89(12):2320-6. doi: 10.1038/sj.bjc.6601428.